Literature DB >> 32296505

Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas.

Guillaume Le Guyader1, Victoire Vieillard1, Karine Andrieux2, Mylène Rollo1, Olivier Thirion1, Pierre Wolkenstein3, Muriel Paul1.   

Abstract

Objectives: In recent years, various formulations containing rapamycin, mainly petrolatum-based, have been tested on facial angiofibromas in tuberous sclerosis. They are often poorly tolerated due to irritation and bleeding. In addition, their effectiveness was insufficient in young adults. The objective of this study was to develop and characterise a hydro-alcoholic gel containing solubilised rapamycin. The stability of the product stored at 4°C was evaluated over 1 year.
Methods: Two different 0.1% rapamycin gels were formulated with or without α-tocopherol and urea. Different methods were used to characterise the gels: HPLC, gas chromatography, pH, visual observation and optical microscopy. A physico-chemical and microbiological stability study was also conducted for 1 year at 4°C.
Results: Gels were physically and microbiologically stable after 1 year at 4°C: organoleptic characteristics and pH unchanged, no significant decrease in rapamycin was observed, tocopherol droplet size was constant and rheological behaviour was not altered. Conclusions: This study describes a new gel formulation to improve skin penetration using various excipients to promote skin tolerance. This study provides, for the first time, detailed stability data for a hydro-alcoholic rapamycin gel. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  angiofibromas; hydrophilic gel; rapamycin; stability; topical formulation; tuberous sclerosis

Mesh:

Substances:

Year:  2018        PMID: 32296505      PMCID: PMC7147563          DOI: 10.1136/ejhpharm-2018-001695

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  22 in total

1.  Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.

Authors:  Rachael S Foster; Lewis J Bint; Anne R Halbert
Journal:  Australas J Dermatol       Date:  2011-12-29       Impact factor: 2.875

2.  Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.

Authors:  M M Mutizwa; D R Berk; M J Anadkat
Journal:  Br J Dermatol       Date:  2011-10       Impact factor: 9.302

3.  Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.

Authors:  Cynthia M C DeKlotz; Alicia E Ogram; Saurabh Singh; Sridhar Dronavalli; Jennifer L MacGregor
Journal:  Arch Dermatol       Date:  2011-09

4.  Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: A prospective study of 25 patients.

Authors:  Nausicaa Malissen; Laurence Vergely; Marguerite Simon; Agathe Roubertie; Marie-Claire Malinge; Didier Bessis
Journal:  J Am Acad Dermatol       Date:  2017-05-11       Impact factor: 11.527

5.  Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.

Authors:  Jenny Tu; Rachael S Foster; Lewis J Bint; Anne R Halbert
Journal:  Australas J Dermatol       Date:  2013-12-22       Impact factor: 2.875

6.  Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.

Authors:  Young In Lee; Ju Hee Lee; Do Young Kim; Kee Yang Chung; Jung U Shin
Journal:  Dermatology       Date:  2018-06-20       Impact factor: 5.366

7.  Glycerol replacement corrects defective skin hydration, elasticity, and barrier function in aquaporin-3-deficient mice.

Authors:  Mariko Hara; A S Verkman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-27       Impact factor: 11.205

Review 8.  Penetration enhancers.

Authors:  Adrian C Williams; Brian W Barry
Journal:  Adv Drug Deliv Rev       Date:  2004-03-27       Impact factor: 15.470

Review 9.  Glycerol and the skin: holistic approach to its origin and functions.

Authors:  J W Fluhr; R Darlenski; C Surber
Journal:  Br J Dermatol       Date:  2008-07-01       Impact factor: 9.302

Review 10.  The role of vitamin E in normal and damaged skin.

Authors:  F Nachbar; H C Korting
Journal:  J Mol Med (Berl)       Date:  1995-01       Impact factor: 4.599

View more
  3 in total

1.  Improved Skin Permeability after Topical Treatment with Serine Protease: Probing the Penetration of Rapamycin by Scanning Transmission X-ray Microscopy.

Authors:  Gregor Germer; Takuji Ohigashi; Hayato Yuzawa; Nobuhiro Kosugi; Roman Flesch; Fiorenza Rancan; Annika Vogt; Eckart Rühl
Journal:  ACS Omega       Date:  2021-04-28

2.  Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed.

Authors:  Guillaume Le Guyader; Bernard Do; Victoire Vieillard; Karine Andrieux; Muriel Paul
Journal:  Pharmaceutics       Date:  2020-11-07       Impact factor: 6.321

3.  Mixed Polymeric Micelles for Rapamycin Skin Delivery.

Authors:  Guillaume Le Guyader; Bernard Do; Ivo B Rietveld; Pascale Coric; Serge Bouaziz; Jean-Michel Guigner; Philippe-Henri Secretan; Karine Andrieux; Muriel Paul
Journal:  Pharmaceutics       Date:  2022-03-04       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.